Immunological Assessment of Chitosan or Trimethyl Chitosan-Coated PLGA Nanospheres Containing Fusion Antigen as the Novel Vaccine Candidates Against Tuberculosis

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Sirwan Zare ◽  
Mona Kabiri ◽  
Yousef Amini ◽  
Adel Najafi ◽  
Fatemeh Mohammadpour ◽  
...  
Keyword(s):  
The Novel ◽  
Vaccine Candidates ◽  
Trimethyl Chitosan ◽  
Fusion Antigen ◽  
Plga Nanospheres

scholarly journals Synthesis and immunological evaluation of synthetic peptide based anti-SARS-CoV-2 vaccine candidates

2021 ◽  
Author(s):  
Qingyu Zhao ◽  
Yanan Gao ◽  
Min Xiao ◽  
Xuefei Huang ◽  
Xuanjun Wu
Keyword(s):  
Synthetic Peptide ◽  
Spike Protein ◽  
Effective Vaccine ◽  
The Novel ◽  
Vaccine Candidates ◽  
Peptide Epitopes ◽  
Novel Coronavirus ◽  
Immunological Evaluation

For prevention of the coronavirus disease 2019 caused by the novel coronavirus SARS-CoV-2, an effective vaccine is critical. Herein, several potential peptide epitopes from the spike protein of SARS-CoV-2 have...

scholarly journals Comparison of Four SARS-CoV-2 Neutralization Assays

Vaccines ◽  
2020 ◽  
Vol 9 (1) ◽  
pp. 13
Author(s):  
Lydia Riepler ◽  
Annika Rössler ◽  
Albert Falch ◽  
André Volland ◽  
Wegene Borena ◽  
...  
Keyword(s):  
Vesicular Stomatitis Virus ◽  
Neutralizing Antibodies ◽  
The Other ◽  
In Vitro Assays ◽  
The Novel ◽  
Effective Protection ◽  
Vaccine Candidates ◽  
Vesicular Stomatitis ◽  
Novel Coronavirus

Neutralizing antibodies are a major correlate of protection for many viruses including the novel coronavirus SARS-CoV-2. Thus, vaccine candidates should potently induce neutralizing antibodies to render effective protection from infection. A variety of in vitro assays for the detection of SARS-CoV-2 neutralizing antibodies has been described. However, validation of the different assays against each other is important to allow comparison of different studies. Here, we compared four different SARS-CoV-2 neutralization assays using the same set of patient samples. Two assays used replication competent SARS-CoV-2, a focus forming assay and a TCID50-based assay, while the other two assays used replication defective lentiviral or vesicular stomatitis virus (VSV)-based particles pseudotyped with SARS-CoV-2 spike. All assays were robust and produced highly reproducible neutralization titers. Titers of neutralizing antibodies correlated well between the different assays and with the titers of SARS-CoV-2 S-protein binding antibodies detected in an ELISA. Our study showed that commonly used SARS-CoV-2 neutralization assays are robust and that results obtained with different assays are comparable.

scholarly journals Identification and Immunological Characterization of Three Potential Vaccinogens against Cryptosporidium Species

2011 ◽  
Vol 18 (11) ◽  
pp. 1796-1802 ◽  
Author(s):  
Patricio A. Manque ◽  
Fernando Tenjo ◽  
Ute Woehlbier ◽  
Ana M. Lara ◽  
Myrna G. Serrano ◽  
...  
Keyword(s):  
The Novel ◽  
Cryptosporidium Hominis ◽  
Content Type ◽  
Vaccine Candidates ◽  
Novel Approach ◽  
Intellectual Abilities ◽  
Significant Impairment ◽  
Life Threatening ◽  
Potential Vaccine ◽  
Cellular Immune

ABSTRACTCryptosporidiosis is a ubiquitous infectious disease, caused by the protozoan parasitesCryptosporidium hominisandCryptosporidium parvum, leading to acute, persistent, and chronic diarrhea with life-threatening consequences in immunocompromised individuals. In developing countries, cryptosporidiosis in early childhood has been associated with subsequent significant impairment in growth, physical fitness, and intellectual abilities. Currently, vaccines are unavailable and chemotherapeutics are toxic and impractical, and agents for immunoprophylaxis or treatment of cryptosporidiosis are a high priority. Availability of the genome sequences forC. hominisandC. parvumprovides new opportunities to procure and examine novel vaccine candidates. Using the novel approach of “reverse vaccinology,” we identified several new potential vaccine candidates. Three of these antigens—Cp15, profilin, and aCryptosporidiumapyrase—were delivered in heterologous prime-boost regimens as fusions with cytolysin A (ClyA) in aSalmonellalive vaccine vector and as purified recombinant antigens, and they were found to induce specific and potent humoral and cellular immune responses, suggesting their potential as new vaccinogens againstCryptosporidiuminfection.

scholarly journals Recommendations for acceleration of vaccine development and emergency use filings for COVID-19 leveraging lessons from the novel oral polio vaccine

npj Vaccines ◽  
2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Natalie Thiel ◽  
Casey Selwyn ◽  
Georgina Murphy ◽  
Shmona Simpson ◽  
Ajoy C. Chakrabarti
Keyword(s):  
Vaccine Development ◽  
Oral Polio Vaccine ◽  
Clinical Development ◽  
Development Plan ◽  
Functional Domains ◽  
The Novel ◽  
Vaccine Candidates ◽  
Polio Vaccine ◽  
Faster Development ◽  
General Guidance

AbstractA new oral polio vaccine, nOPV2, has become the first vaccine to pursue a WHO Emergency Use Listing. Many lessons were learned as part of the accelerated development plan and submission, which have been categorized under the following sections: regulatory, clinical development, chemistry manufacturing and controls, and post-deployment monitoring. Efforts were made to adapt findings from these studies to COVID-19 vaccine candidates. Specific concepts for accelerating COVID-19 vaccine development across multiple functional domains were also included. The goals of this effort were twofold: (1) to help familiarize vaccine developers with the EUL process; and (2) to provide general guidance for faster development and preparations for launch during the COVID-19 pandemic.

scholarly journals Biological properties the novel application of N-trimethyl chitosan nanospheres as a stabilizer and preservative in tetanus vaccine

2021 ◽  
Vol 10 (1) ◽  
pp. 24
Author(s):  
Majdedin Ghalavand ◽  
Mojtaba Saadati ◽  
Jafar Salimian ◽  
Ebrahim Abbasi ◽  
Ghader Hosseinzadeh ◽  
...  
Keyword(s):  
Biological Properties ◽  
The Novel ◽  
Trimethyl Chitosan ◽  
Tetanus Vaccine

scholarly journals Importance of Pediatric Studies in SARS-CoV-2 Vaccine Development

2021 ◽  
Vol 26 (4) ◽  
pp. 418-421
Author(s):  
Erin Wilson ◽  
Jennifer Girotto ◽  
Nicole Passerrello ◽  
Sylvia Stoffella ◽  
Dhara Shah ◽  
...  
Keyword(s):  
Vaccine Development ◽  
Pediatric Population ◽  
The Novel ◽  
Efficacy Data ◽  
Safety And Efficacy ◽  
Vaccine Candidates ◽  
Inflammatory Syndrome

Vaccination efforts against COVID-19 must include the pediatric population, not only to protect children and their families from the virus, but also to support a safe return to in-person schooling. Given the novel methodologies and targets used in the COVID-19 vaccines and the potential for multisystem inflammatory syndrome-children, it is insufficient to extrapolate safety and efficacy data between different vaccine candidates or from adult studies. Adequate enrollment in pediatric studies for COVID-19 vaccines is crucial. The Pediatric Pharmacy Association supports continued research, surveillance, and transparency for COVID-19 vaccines in the pediatric population, including those younger than 12 years of age.

scholarly journals Strategies and Challenges in the Development of Coronavirus Disease-2019 Vaccine

2021 ◽  
Vol 6 (1) ◽  
pp. 1-10
Author(s):  
Pratibha Gupta ◽  
Keyword(s):  
The Novel ◽  
S Protein ◽  
Angiotensin Converting Enzyme 2 ◽  
Vaccine Candidates ◽  
Advantages And Disadvantages ◽  
Vaccination Strategies ◽  
Nucleic Acid Vaccine ◽  
Effective Interventions ◽  
Coronavirus Infection ◽  
Novel Coronavirus

The novel coronavirus infection (coronavirus disease-2019 (COVID-19)) emerged from Wuhan in the Hubei Province of China in late 2019. Millions of people were infected with COVID-19 pandemic due to the long incubation period of the virus inside the human body and the dearth of available treatments or vaccines. High transmission rates created havoc, which highlighted the urgent need for effective interventions to stop the spread and clinical impact of the virus on patients and populations. Previous research on severe acute respiratory syndrome coronavirus (SARS-CoV) provides information on vaccination strategies that could inform how governments approach the elimination of this novel coronavirus. Numerous efforts have been made to develop vaccines against Middle East respiratory syndrome (MERS) and SARS. The spike glycoprotein or S protein is the critical target for most of the drugs and vaccines against coronavirus. The virus uses the spike (S) protein for entering the host cell, by interacting with the receptor called angiotensin converting enzyme-2 (ACE2). Various vaccine platforms are available such as nucleic acid vaccine, protein-based vaccines, virus-vectored vaccines and live or attenuated vaccines, with each having their advantages and disadvantages. This review focuses on the overview of different vaccine candidates used, those currently in development, and the challenges encountered while developing effective vaccines.

The novel steroidal glycoside from the dried bulb of Allium Macrostemon Bunge inhibits platelet activation

2010 ◽  
Vol 34 (8) ◽  
pp. S33-S33
Author(s):  
Wenchao Ou ◽  
Haifeng Chen ◽  
Yun Zhong ◽  
Benrong Liu ◽  
Keji Chen
Keyword(s):  
Platelet Activation ◽  
The Novel ◽  
Steroidal Glycoside ◽  
Allium Macrostemon
Sign in / Sign up

Export Citation Format

Share Document